Skip to main content
. Author manuscript; available in PMC: 2010 Feb 15.
Published in final edited form as: Circ Res. 2008 Dec 18;104(3):403–411. doi: 10.1161/CIRCRESAHA.108.190918

Figure 1.

Figure 1

Metformin improved survival following permanent occlusion of left coronary artery. (A) Murine in vivo permanent left coronary artery (LCA) occlusion protocol. (B) Kaplan-Meier survival curve following metformin therapy in mice during the 4 wk post myocardial infarction. Metformin significantly improved survival by 47% (p < 0.05) compared to vehicle treated mice. (C) Myocardial infarct size analysis in a subset of animals subjected to 24 hr of myocardial ischemia. Area-at-risk (AAR) as a percentage of the left ventricle (LV) was similar between both groups. Metformin (125 μg/kg) administration did not attenuate myocardial infarct size following permanent LCA occlusion. (D) LV function was evaluated in a subset of animals at 4 wks of myocardial ischemia. Ejection fraction at baseline and following myocardial ischemia were similar in both groups. Values are means ± S.E.M. Numbers inside bars indicate the number of animals that were investigated in each group. *** p < 0.001 vs. Baseline. Veh = vehicle, Met QD = Metformin QD.